Method for purifying antibodies
阅读说明：本技术 纯化抗体的方法 (Method for purifying antibodies ) 是由 G.派特乔尼克 I.N.N.纳姆布西里 M.谢夫斯 A.霍华德 科恩 M.(M.) 于 2018-05-09 设计创作，主要内容包括：公开了一种分离抗体的方法。所述方法包括使疏水性螯合剂、非离子型去污剂和金属离子接触,以产生包含所述疏水性螯合剂、所述去污剂和所述金属离子的聚集体；和在使得所述抗体能够分配至所述聚集体中的条件下使所述聚集体与包含所述抗体的培养基接触。还公开了用于分离所述抗体的试剂盒。(A method of isolating an antibody is disclosed. The method comprises contacting a hydrophobic chelator, a non-ionic detergent, and a metal ion to produce an aggregate comprising the hydrophobic chelator, the detergent, and the metal ion; and contacting the aggregate with a medium comprising the antibody under conditions that enable partitioning of the antibody into the aggregate. Also disclosed are kits for isolating the antibodies.)
1. A method of isolating an antibody, the method comprising:
(a) contacting a hydrophobic chelator, a non-ionic detergent and a metal ion to produce an aggregate comprising the hydrophobic chelator, the detergent and the metal ion; and
(b) contacting the aggregate with a medium comprising the antibody under conditions that enable partitioning of the antibody into the aggregate, thereby isolating the antibody.
2. A kit comprising a hydrophobic chelator, a non-ionic detergent, a buffer at a pH between 3 and 6, and a metal ion.
3. A kit comprising a hydrophobic chelator, a polysorbate surfactant, and a metal ion.
4. The method of claim 1, wherein the culture medium comprises a cell lysate.
5. The method of claim 4, wherein the cell lysate is a whole cell lysate.
6. The method of claim 1, wherein the culture medium comprises a hybridoma culture medium.
7. The method of claim 1 or 6, wherein the medium comprises serum albumin.
8. The method of claim 4, wherein the cell lysate has no organelles greater than about 2 microns.
9. The method of claim 1, wherein said conditions of step (b) comprise salt levels below 100 mM.
10. The method of claim 1, further comprising solubilizing the antibody after step (b).
11. The method of claim 10, wherein the solubilization is performed with a buffer having a pH between 3 and 6.
12. The method of claim 10, wherein the solubilization is performed with a buffer having a pH between 3.8 and 4.
13. The method of claim 11, wherein the buffer further comprises a salt.
14. The kit of claim 3, further comprising a buffer having a pH between 3 and 6.
15. The kit or method of any one of claims 2, 11 or 14, wherein the buffer is a carboxylic acid buffer.
16. The kit or method of any one of claims 2, 11 or 14, wherein the buffer comprises amino acids.
17. The kit or method of claim 11, 14 or 15, wherein the carboxylic acid buffer is selected from the group consisting of isoleucine, valine, glycine and sodium acetate.
18. The method or kit of claim 1 or 2, wherein the non-ionic detergent is a polysorbate surfactant.
19. The method or kit of claim 3 or 18, wherein the polysorbate surfactant is selected from polysorbate 20, polysorbate 40, polysorbate 60, and polysorbate 80.
20. The method or kit of any one of claims 1-3, wherein the hydrophobic chelator comprises 8-hydroxyquinoline.
21. The method or kit of any one of claims 1-3, wherein the hydrophobic chelator comprises a phenanthroline.
22. The method or kit of claim 21, wherein the phenanthroline is selected from the group consisting of N- (1, 10-phenanthrolin-5-yl) carboxamide (Phen-C1), N- (1, 10-phenanthrolin-5-yl) acetamide (Phen-C2), N- (1, 10-phenanthrolin-5-yl) propionamide (Phen-C3), N- (1, 10-phenanthrolin-5-yl) butyramide (Phen-C4), N- (1, 10-phenanthrolin-5-yl) valeramide (Phen-C5), N- (1, 10-phenanthrolin-5-yl) hexanamide (Phen-C6), N- (1, 10-phenanthrolin-5-yl) heptanamide (Phen-C7), N- (1, 10-phenanthroline-5-yl) octanoamide (Phen-C8), N- (1, 10-phenanthroline-5-yl) nonanamide (Phen-C9) and N- (1, 10-phenanthroline-5-yl) decanoamide (Phen-C10).
23. The method or kit of claim 21, wherein the phenanthroline is selected from the group consisting of bathophenanthroline, N- (1, 10-phenanthrolin-5-yl) hexanamide (Phen-C6), N- (1, 10-phenanthrolin-5-yl) decanamide (Phen-C10), and N- (1, 10-phenanthrolin-5-yl) octanamide (Phen-C8).
24. The method or kit of claim 23, wherein the phenanthroline is a bathophenanthroline.
25. The method or kit of any one of claims 1-3, wherein the metal ion is a divalent metal ion.
26. The method or kit of claim 25, wherein the divalent metal ion is selected from Zn2+、Fe2+、Mn2+、Ni2+And Co2 +。
27. The method or kit of claim 26, wherein the divalent metal ion is selected from Zn2+And Fe2+。
28. The method of claim 1, wherein said hydrophobic chelator is present in said aqueous solution at a concentration in the range of about 0.1% to about 10% (v/v).
29. The method of claim 1, wherein said metal ion is present in said aqueous solution at a concentration in the range of about 0.1% to about 10% (v/v).
30. The method of claim 4, wherein the cell lysate is derived from bacterial cells.
31. The method of claim 4, wherein the cell lysate is derived from mammalian cells.
32. The method of claim 31, wherein the mammalian cell is a chinese hamster ovary Cell (CHO).
33. The method of claim 1, wherein the antibody is a humanized antibody.
34. The method of claim 1, wherein the antibody is a recombinant antibody.
35. The method of claim 1, wherein the antibody is selected from the group consisting of IgA, IgD, IgE, IgM and IgG.
36. The method of claim 35, wherein the IgG is IgG1, IgG2, IgG3, or IgG 4.
Field and background of the invention
The present invention, in some embodiments thereof, relates to methods and kits for purifying antibodies.
Monoclonal antibodies (mabs) are the recombinant proteins most commonly used as therapeutic agents at present; it was the largest bioproduct sales category in the united states in 2012. Significant increases in their expression levels from as low as milligrams to grams per liter concentration, and the number of hundreds of kilograms to tons some of which would require, present a continuing challenge to industrial purification processes that can effectively capture mabs from complex mixtures. This is typically achieved via ProA chromatography as an initial capture step, typically resulting in high recovery (>95%), purity (>95%), while removing most of the host DNA, viral contaminants and leached ProA.
These excellent features make ProA chromatography the gold standard for antibody production. However, there is an incentive to develop more economical alternatives due to the high cost of ProA resins relative to non-affinity polymeric supports (e.g., ion exchangers). This motivation has further proven reasonable when considering the current and future global biotechnological demand (i.e., many tons of purified mabs per year) that represents hundreds of different therapeutic mabs being developed, all of which are aimed at targeting various cancers, autoimmune and inflammatory disorders.
It is believed that the use of ProA and chromatographic strategies often represents an inherent "productivity bottleneck" for mAb industrial purification, which can account for up to 80% of the total manufacturing cost, thus making any antibody capture method that does not require the following an attractive alternative to future pharmaceutical needs: (a) ProA as ligand and/or (b) chromatography as the main capture step.
Background art includes Patthornick et al, Bioconjugate Chemistry, 2013, Volume24, 1270-,J. Chromatogr A.(1994) 661, 13-23; Manske etal.,J. Immunol Methods(1997) 2008, 65-73; Follman and FahrnerJ. Chromatogr A.(2004) 1024, 79-85 and Ghosh and Wang,J. Chromatogr A.(2006) 1107, 104-109。
summary of The Invention
A new concept of antibody purification was discovered. Human immunoglobulin g (higg) and mouse IgG were almost quantitatively (95% by density) partitioned into aggregates of non-ionic detergent, metal ions and hydrophobic chelator, while the majority (> 85% by density) of non-IgG proteins (i.e. impurities) were rejected. This process is highly specific as it relies on the presence of chelating agents and metals. Antibodies adsorbed or embedded within aggregates can be extracted without concomitant dissolution of the aggregates and resulting in a purer IgG preparation (-95% by density). The overall yield of the process includes: ig partition and extraction ranged between 40-46% (by density). Circular dichroism spectroscopy (CD) demonstrated that the secondary structure of the extracted hIgG was preserved.
An aspect of some embodiments of the invention provides a method of isolating an antibody, the method comprising:
(a) contacting a hydrophobic chelator, a non-ionic detergent and a metal ion to produce an aggregate comprising the hydrophobic chelator, the detergent and the metal ion; and
(b) contacting the aggregate with a medium comprising the antibody under conditions that enable partitioning of the antibody into the aggregate, thereby isolating the antibody.
An aspect of some embodiments of the invention provides a kit comprising a hydrophobic chelating agent, a non-ionic detergent, a buffer having a pH between 3 and 6, and a metal ion.
An aspect of some embodiments of the invention provides a kit comprising a hydrophobic chelating agent, a polysorbate surfactant, and a metal ion.
According to some embodiments of the invention, the medium comprises a cell lysate.
According to some embodiments of the invention, the cell lysate is a whole cell lysate.
According to some embodiments of the invention, the cell lysate has no organelles larger than about 2 microns.
According to some embodiments of the invention, the conditions of step (b) comprise a salt level below 100 mM.
According to some embodiments of the invention, the method further comprises solubilizing the antibody after step (b).
According to some embodiments of the invention, the solubilization is performed with a buffer having a pH between 3 and 6.
According to some embodiments of the invention, the solubilization is performed with a buffer having a pH between 3.8 and 4.
According to some embodiments of the invention, the buffer further comprises a salt.
According to some embodiments of the invention, the kit further comprises a buffer at a pH between 3 and 6.
According to some embodiments of the invention, the buffer is a carboxylic acid buffer.
According to some embodiments of the invention, the carboxylic acid buffer is selected from isoleucine, valine, glycine and sodium acetate.
According to some embodiments of the invention, the buffer comprises an amino acid.
According to some embodiments of the invention, the non-ionic detergent is a polysorbate surfactant.
According to some embodiments of the invention, the polysorbate surfactant is selected from
According to some embodiments of the invention, the hydrophobic chelating agent comprises 8-hydroxyquinoline.
According to some embodiments of the invention, the hydrophobic chelating agent comprises phenanthroline.
According to some embodiments of the invention, the phenanthroline is selected from the group consisting of N- (1, 10-phenanthrolin-5-yl) formamide (Phen-C1), N- (1, 10-phenanthrolin-5-yl) acetamide (Phen-C2), N- (1, 10-phenanthrolin-5-yl) propionamide (Phen-C3), N- (1, 10-phenanthrolin-5-yl) butyramide (Phen-C4), N- (1, 10-phenanthrolin-5-yl) valeramide (Phen-C5), N- (1, 10-phenanthrolin-5-yl) hexanamide (Phen-C6), N- (1, 10-phenanthrolin-5-yl) heptanamide (Phen-C7), N- (1, 10-phenanthroline-5-yl) octanoamide (Phen-C8), N- (1, 10-phenanthroline-5-yl) nonanamide (Phen-C9) and N- (1, 10-phenanthroline-5-yl) decanoamide (Phen-C10).
According to some embodiments of the invention, the phenanthroline is selected from the group consisting of bathophenanthroline, N- (1, 10-phenanthrolin-5-yl) hexanamide (Phen-C6), N- (1, 10-phenanthrolin-5-yl) decanamide (Phen-C10) and N- (1, 10-phenanthrolin-5-yl) octanamide (Phen-C8).
According to some embodiments of the invention, the phenanthroline is a bathophenanthroline.
According to some embodiments of the invention, the metal ion is a divalent metal ion.
According to some embodiments of the invention, the divalent metal ion is selected from Zn2+、Fe2+、Mn2+、Ni2+And Co2+。
According to some embodiments of the invention, the divalent metal ion is selected from Zn2+And Fe2+。
According to some embodiments of the invention, the hydrophobic chelating agent is present in the aqueous solution at a concentration in the range of about 0.1% to about 10% (v/v).
According to some embodiments of the invention, the culture medium comprises a hybridoma culture medium.
According to some embodiments of the invention, the medium comprises serum albumin.
According to some embodiments of the invention, the metal ion is present in the aqueous solution at a concentration in the range of about 0.1% to about 10% (v/v).
According to some embodiments of the invention, the cell lysate is derived from bacterial cells.
According to some embodiments of the invention, the cell lysate is derived from mammalian cells.
According to some embodiments of the invention, the mammalian cell is a chinese hamster ovary Cell (CHO).
According to some embodiments of the invention, the antibody is a humanized antibody.
According to some embodiments of the invention, the antibody is a recombinant antibody.
According to some embodiments of the invention, the antibody is selected from IgA, IgD, IgE, IgM, and IgG.
According to some embodiments of the invention, the IgG is IgG1, IgG2, IgG3 or
Unless defined otherwise, all technical and/or scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of embodiments of the present invention, the following description of exemplary methods and/or materials. In case of conflict, the patent specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be necessarily limiting.
Brief Description of Drawings
Some embodiments of the invention are described herein by way of example only and with reference to the accompanying drawings. Referring now in specific detail to the drawings, it is stressed that the particulars shown are by way of example and for purposes of illustrative discussion of embodiments of the present invention. In this regard, it will be apparent to those skilled in the art from this description, taken in conjunction with the accompanying drawings, how embodiments of the present invention may be practiced.
Fig. 1 is a schematic illustration of the process disclosed herein, according to an embodiment of the invention. After incubation with a hydrophobic chelating agent, micelles consisting of a non-ionic detergent are converted into engineered micelles and in the presence of Fe2+Specific clustering in the presence of ions to form a complex of [ metal: chelating agent]Complex interconnected micellar aggregates. The antibody partitions into micellar aggregates, whereas other more hydrophilic proteins do not. In thatFurther extraction of target IgG was done under defined conditions that kept the detergent aggregates intact.
FIGS. 2A-D are photographs illustrating the effect of optical microscopy and low temperature TEM analysis. Optical microscopy: A. tween-20 micelle Jing [ (bathophenanthroline)3:Fe2+]The red complex was conjugated. B. E.g. A but in the absence of Fe2+Control experiment in case (1). Low-temperature TEM: C. tween-20 micelle Jing [ (bathophenanthroline)3:Fe2+]And (4) complex conjugation. D. Control experiments with Tween-20 micelles only (black dots).
FIGS. 3A-C are photographs illustrating the results of SDS-PAGE analysis. A. Process feasibility and dependence on metals and chelating agents. Lane 1: e.coli lysate; lane 2: a target hIgG; lane 3: in the presence of [ (bathophenanthroline)3:Fe2+]Precipitate composition in case of complex; lanes 4-5: as in
Fig. 4A-C illustrate process efficiency in the presence of different divalent metal cations: lane 1: e.coli lysate; lane 2: a target hIgG; lane 3: in the presence of [ (bathophenanthroline)3:Fe2+]Precipitate composition in case of complex; lanes 4-5: as in
FIGS. 5A-B are schematic diagrams of a commonly used large-scale mAb purification process (A) and an alternative route (B) using Tween-20 aggregates. UF and DF represent ultrafiltration and diafiltration, respectively.
FIGS. 6A-C illustrate SDS-PAGE and CD analysis. A. hIgG was extracted from Tween-20 aggregates. Lane 1: e.coli lysate; lane 2: a target hIgG; lanes 3-8: composition of supernatant after incubation with the indicated buffer and salt concentration. B. Such as a but mouse IgG is present. The gel was stained with coomassie. C. CD analysis of hIgG extracted from Tween-20 aggregates in the presence of 50 mM AcOH (pH 4.6) in 20mM NaCl.
FIGS. 7A-D illustrate the effect of BSA on the purification of human and mouse IgG in serum-free medium. A. Human igg (higg) capture: lane 1: hIgG and BSA; lanes 2-10: composition of the pellet obtained after incubation of Tween-20 aggregates with hIgG (1mg/ml) and BSA at the indicated concentration in serum-free medium as described in the experiment. B: the composition of the supernatant after incubation of the corresponding pellet produced in gel A-I (lanes 2-10) with 50 mM isoleucine at pH 3.8 was as described in the experiment. C and D are as described in A but mouse IgG is present. Letter: h and L represent the reduced heavy and light chains, respectively, of the antibody of interest. Letter a points to the detergent aggregate zone. The gel was stained with coomassie.
FIGS. 8A-E illustrate extraction buffer efficiency, circular dichroism analysis, and DLS analysis. A. Effect of buffer composition on hIgG extraction. Lane 1: hIgG and BSA; lane 2: composition of the pellet obtained after incubation of Tween-20 aggregates with hIgG (1mg/ml) and BSA (0.5 mg/ml) in serum-free medium as described in the experiment; lanes 3-9: the composition of the supernatant after extraction of hIgG from the pellet produced under the conditions shown in
FIGS. 9A-B: ELISA analysis of extracted IgG. Polyclonal anti-BSAIgG from rabbit (naked) or sheep (biotinylated) was subjected to the purification method presented and extracted from Tween-20 aggregates with the indicated amino acid buffer (50 mM) (pH 3.8) at 32 deg.C (5 min). The ability of these purified abs to bind to their target epitope on BSA was determined by ELISA assay as described in materials and methods. The data presented were dependent on at least 12 independent experiments.
FIGS. 10A-B IgM was purified with Tween-20 aggregates. A. Specificity of IgM capture. Lane 1: hIgG; lane 2: BSA; lane 3: bovine polyclonal IgM; lane 4: IgM + BSA mix (total used); lane 5: composition of the pellet after incubation of the IgM + BSA mixture with [ Tween-20: batho: Fe2+ ] aggregates and removal of the supernatant. Asterisks point to stained Tween-20 aggregates; lanes 6-7: as in
Description of specific embodiments of the invention
The present invention, in some embodiments thereof, relates to methods and kits for purifying antibodies. In particular, the method involves an alternative route to antibody capture without the use of the common ligand protein a (proa).
Before explaining at least one embodiment of the invention in detail, it is to be understood that the invention is not necessarily limited in its application to the details described below or illustrated by the examples. The invention is capable of other embodiments or of being practiced or carried out in various ways.
Purification of antibodies typically uses protein a (proa) chromatography as an initial capture step. However, proA chromatography is very expensive, creating a "productivity bottleneck".
Thus, the present inventors have sought alternative methods for purifying IgG. Although antibodies are highly hydrophilic, the present inventors have surprisingly found that conjugated Tween-20 (polysorbate 20) micelles, which are commonly used for the isolation of hydrophobic proteins, can also be used as an alternative to the commonly used ProA columns for the isolation of antibodies. The experimental result shows that the micelle composed of the nonionic detergent Tween-20 can exist hydrophobicity [ (bathophenanthroline)3:Fe2+]Specific conjugation in the case of red complex resulted in the formation of a particulate red precipitate (fig. 2A). Micellar conjugation was found to be highly specific, as it did not occur in the absence of metals (fig. 2B) or chelators (not shown). Analysis of the Red aggregate by Low temperature TEM indicated, [ (Red phenanthroline)3:Fe2+]The complexes lead to various aggregated forms, some of which reach a size of 100 nm (fig. 2C), while in the absence of complexes, micellar dispersions appear to be monodisperse (fig. 2D). These results are [ (bathophenanthroline)3:Fe2+]The ability of the complex to induce micellar clustering provides direct evidence.
To demonstrate IgG purification, a mixture of target human IgG in e.coli lysate (used as an artificial contamination background) was added to pre-formed Tween-20 aggregates. After 5 minutes of incubation, the mixture was centrifuged and the impurities present in the supernatant were discarded. The precipitate was analyzed by SDS-PAGE, revealing the presence of reduced heavy and light chains (FIG. 3A, lane 3). Furthermore, the majority of the impurities present in the system (fig. 3A, lane 1) were not present in the precipitate (fig. 3A, lane 3), consistent with the following assumptions: water soluble proteins other than IgG (on average more polar than IgG) will not associate with Tween-20 aggregates, whereas antibody molecules will associate.
To demonstrate the generality of the process, the inventors also investigated the dependence of IgG partitioning behavior with polyclonal mouse IgG (fig. 3C) and found a very similar pattern. The fact that IgG from different biological sources (human and mouse) efficiently partition into Tween-20 aggregates suggests that the present purification strategy may not be related to the specific amino acid sequence of the IgG of interest. This in turn may obviate the need to develop specific purification protocols for each therapeutic monoclonal antibody, thereby allowing for a standardized purification platform.
Two exemplary buffer systems (NaOAc pH 4.6 and Gly pH4) demonstrated their ability to extract hIgG and mouse IgG from Tween-20 aggregates while significantly inhibiting aggregate solubilization and concomitant extraction of hydrophobic impurities (fig. 6A-B). Retention of the secondary structure of hIgG was studied with Circular Dichroism (CD) (fig. 6C). CD analysis showed no significant change in the secondary structure of the purified hIgG (fig. 6C).
Other buffer systems were also shown to be able to extract both hIgG and mouse IgG from Tween-20 aggregates-see figure 8A.
While further simplifying the practice of the invention, the inventors show that this purification strategy can also be used to purify antibodies from hybridoma serum-free media (fig. 7A-D).
The inventors' antibodies remained active after purification (see FIGS. 9A-B).
In addition, the inventors show that the purification scheme is effective not only for monomeric antibodies (IgG) but also for pentameric antibodies (IgM) -see fig. 10A-B.
The purification strategy presented here has some inherent advantages: (A) the raw material cost is reduced; (B) lower purification yields due to ligand denaturation are not involved as no specific ligand is included. (C) The limited capacity of affinity columns (currently 30gr/L) is not suitable for the current technology because it does not rely on the use of columns and affinity resins; and (D) speed-large scale antibody purification processes currently in use take 1-2 days. It is likely that the removal of one (or both) chromatographic steps will significantly shorten the total purification time, thereby contributing to production efficiency.
Accordingly, a first aspect of the invention provides a method of isolating an antibody, the method comprising:
(a) contacting a hydrophobic chelator, a non-ionic detergent and a metal ion to produce an aggregate comprising the hydrophobic chelator, the detergent and the metal ion; and
(b) contacting the aggregate with a medium comprising the antibody under conditions that enable partitioning of the antibody into the aggregate, thereby isolating the antibody.
The term "antibody" as used herein includes antibodies capable ofIntact molecules capable of binding to an epitope of an antigen and functional fragments thereof (e.g. Fab, F (ab')2Fv, scFv, dsFv or single domain molecules (such as VH and VL)).
Suitable antibody fragments contemplated by the invention include Complementarity Determining Regions (CDRs) of an immunoglobulin light chain (referred to herein as "light chain"), complementarity determining regions of an immunoglobulin heavy chain (referred to herein as "heavy chain"), variable regions of the light chain, variable regions of the heavy chain, light chain, heavy chain, Fd fragments, and antibody fragments comprising substantially the entire variable regions of both the light and heavy chains, such as Fv, single chain Fv (scFv), disulfide stabilized Fv (dsFv), Fab 'and F (ab')2。
The terms "complementarity determining regions" or "CDRs" are used interchangeably herein to refer to antigen binding regions present within the variable regions of heavy and light chain polypeptides. Typically, antibodies comprise 3 CDRs in each VH (CDR H1 or H1; CDR H2 or H2; and CDR H3 or H3), and 3 CDRs in each VL (CDR L1 or L1; CDR L2 or L2; and CDR L3 or L3).
The identity of the amino acid residues in a particular antibody that make up a variable region or CDR can be determined using methods well known in the art and include the following: such as sequence variability as defined by Kabat et al (see, e.g., Kabat et al, 1992, Sequences of Proteins of Immunological Interest, 5th ed., Public health service, NIH, Washington D.C.), the location of structural loop regions as defined by Chothia et al (see, e.g., Chothia et al, Nature 342:877-TMSee Martin et al, 1989, Proc. Natl Acad Sci USA, 86:9268, and the website www (dot) bio-orf-org (dot) uk/abs), the trade-offs between Kabat and Chothia, the complex crystal structures and "conformational definitions" that can be defined by contact (see MacCallum et al, J. mol. biol. 262:732-745, 1996) (see, e.g., Makabe et al, Journal of Biological Chemistry, 283:1156-1166, 2008).
As used herein, "variable region" and "CDR" may refer to variable regions and CDRs defined by any method known in the art, including combinations of methods.
A functional antibody fragment comprising all or substantially all of the variable regions of both the light and heavy chains is defined as follows:
(i) fv, defined as a genetically engineered fragment consisting of the Variable Light (VL) and Variable Heavy (VH) chains, represented as two chains;
(ii) single chain ("scFv"), a genetically engineered single chain molecule comprising a light chain variable region and a heavy chain variable region linked as a genetically fused single chain molecule by a suitable polypeptide linker;
(iii) disulfide stabilized Fv ("dsFv"), engineered antibody comprising a light chain variable region and a heavy chain variable region linked by an engineered disulfide bond;
(iv) fab, a fragment of an antibody molecule containing a monovalent antigen-binding portion of the antibody molecule, which can be obtained by treating the intact antibody with the enzyme papain to produce Fd fragments (consisting of its variable and CH1 domains) of the intact light and heavy chains;
(v) fab ', antibody molecule fragments containing monovalent antigen-binding portions of the antibody molecule, which can be obtained by treatment of the whole antibody with the enzyme pepsin, followed by reduction (two Fab' fragments are obtained per antibody molecule);
(vi) f (ab ') 2, a fragment of an antibody molecule containing a monovalent antigen-binding portion of the antibody molecule, which can be obtained by treating an intact antibody with the enzyme pepsin (i.e. a dimer of Fab' fragments bound together by two disulfide bonds); and
(vii) single domain antibodies or nanobodies consist of a single VH or VL domain that exhibits sufficient affinity for the antigen.
In one embodiment, the antibody is a polyclonal antibody.
In another embodiment, the antibody is a monoclonal antibody.
In yet another embodiment, the antibody is a recombinant antibody.
In yet another embodiment, the antibody is a humanized antibody.
In still other embodiments, the antibody is IgA, IgD, IgE, and IgG (e.g., IgG1, IgG2, IgG3, or IgG 4).
In still other embodiments, the antibody is an IgM.
Methods for generating polyclonal and monoclonal Antibodies and fragments thereof are well known in the art (see, e.g., Harlowand Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, New York, 1988, incorporated herein by reference).
Antibody fragments of some embodiments of the invention may be prepared by proteolysis of antibodies or by expression of DNA encoding the fragment in E.coli or mammalian cells (e.g., Chinese hamster ovary cell culture or other protein expression systems). Antibody fragments can be obtained by pepsin or papain digestion of whole antibodies by conventional methods. For example, antibody fragments can be produced by enzymatic cleavage of the antibody with pepsin to provide a 5S fragment denoted F (ab') 2. The fragment can be further cleaved using a thiol reducing agent, and optionally a protecting group for the sulfhydryl groups resulting from disulfide bond cleavage, to produce a 3.5S Fab' monovalent fragment. Alternatively, enzymatic cleavage using pepsin directly produces two monovalent Fab' fragments and one Fc fragment.
Such methods are described, for example, by golden enberg, U.S. patent nos. 4036945 and 4331647, and references contained therein, which are hereby incorporated by reference in their entirety. See also Porter, R.R. [ biochem. J.73: 119-126 (1959) ]. Other methods of cleaving antibodies, such as isolating the heavy chain to form monovalent light-heavy chain fragments, further cleaving fragments or other enzymatic, chemical or genetic techniques may also be used, so long as the fragments bind to the antigen recognized by the intact antibody.
Fv fragments comprise an association of VH and VL chains. As described by Inbar et al, this association can be non-covalent [ Proc.nat' l Acad. Sci. USA 69:2659-62 (1972) ]. Alternatively, the variable chains may be linked by intermolecular disulfide bonds or crosslinked by chemicals such as glutaraldehyde. Preferably, the Fv fragment comprises VH and VL chains connected by a peptide linker. These single-chain antigen binding proteins (sFv) are prepared by constructing a structural gene comprising DNA sequences encoding VH and VL domains linked by oligonucleotides. The structural gene is inserted into an expression vector, which is then introduced into a host cell (e.g., E.coli). Recombinant host cells synthesize a single polypeptide chain with a linker peptide bridging two V domains. Methods for producing sFvs are described, for example, by [ Whitlow and Filpula, Methods 2: 97-105 (1991); Bird et al, Science 242:423-426 (1988); Pack et al, Bio/Technology 11:1271-77 (1993); and U.S. Pat. No. 4946778, which are hereby incorporated by reference in their entirety.
Another form of antibody fragment is a peptide encoding a single Complementarity Determining Region (CDR). CDR peptides ("minimal recognition units") can be obtained by constructing genes encoding the CDRs of an antibody of interest. Such a gene is prepared, for example, by synthesizing a variable region from RNA of an antibody-producing cell using polymerase chain reaction. See, e.g., Larrick and Fry [ Methods, 2:106-10 (1991) ].
Humanized forms of non-human (e.g., murine) antibodies are immunoglobulins, immunoglobulin chains or fragments thereof (e.g., Fv, Fab ', F (ab')2Or other antigen binding subsequence of an antibody).
Humanized antibodies include human immunoglobulins (recipient antibody) in which residues from a Complementarity Determining Region (CDR) of the recipient are substituted with residues from a CDR of a non-human species (donor antibody), such as mouse, rat or rabbit, having the desired specificity, affinity and capacity. In some cases, Fv framework residues of the human immunoglobulin are substituted with corresponding non-human residues.
Humanized antibodies may also comprise residues that are not present in either the recipient antibody or the imported CDR or framework sequences. Typically, a humanized antibody will comprise substantially all of at least one (and typically two) variable domain, wherein all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin consensus sequence. Most preferably, the humanized antibody will also comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin [ Jones et al, Nature, 321:522-525 (1986); Riechmann et al, Nature, 332:323-329 (1988); and Presta, curr. Op. struct. biol., 2:593-596 (1992) ].
Methods for humanizing non-human antibodies are well known in the art. Typically, humanized antibodies have one or more amino acid residues introduced from a non-human source. These non-human amino acid residues are commonly referred to as import residues, which are typically taken from an import variable domain. Humanization can be essentially carried out by replacing the corresponding sequence of a human antibody with rodent CDRs or CDR sequences according to the method of Winter and coworkers [ Jones et al, Nature, 321:522-525 (1986); Riechmann et al, Nature 332:323-327 (1988); Verhoeyen et al, Science, 239:1534-1536 (1988) ]. Thus, such humanized antibodies are chimeric antibodies (U.S. Pat. No. 4816,567) in which substantially less than an entire human variable domain has been substituted with the corresponding sequence from a non-human species. In fact, humanized antibodies are generally human antibodies in which some CDR residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies. Human antibodies can also be produced using various techniques known in the art, including phage display libraries [ Hoogenboom and Winter, J. mol. biol., 227:381 (1991); Marks et al, J. mol. biol., 222:581 (1991) ]. The techniques of Cole et al and Boerner et al can also be used to prepare human Monoclonal Antibodies (Cole et al, Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, p.77 (1985) and Boerner et al, J. Immunol., 147(1):86-95 (1991)).
Similarly, human antibodies can be prepared by introducing human immunoglobulin loci into transgenic animals (e.g., mice in which endogenous immunoglobulin genes have been partially or completely inactivated). After challenge, human antibody production was observed, which was very similar in all respects to that seen in humans, including gene rearrangement, assembly, and antibody repertoire. This process is described, for example, in U.S. patent nos. 5545807, 5545806, 5569825, 5625126, 5633425, 5661016 and the following scientific disclosures: marks et al, Bio/
When using recombinant techniques, the antibodies can be produced intracellularly, in the periplasmic space, or directly secreted into the culture medium. If the antibody is produced intracellularly, as a first step, particulate debris of the host cells or lysed cells can be removed, for example, by centrifugation or ultrafiltration. When the antibody is secreted into the culture medium, a commercially available protein concentration filter (e.g., Amicon) can be used firstTMOr Millipore PelliconTMUltrafiltration unit) to concentrate the supernatant from such an expression system.
Cell lysis can be performed by a variety of methods, including mechanical shear, osmotic shock, or enzymatic treatment. This disruption releases the entire contents of the cells into the homogenate and additionally produces subcellular debris that is difficult to remove due to its small volume. These are usually removed by differential centrifugation or by filtration. When secreting antibodies, commercially available protein concentration filters (e.g., Amicon) are typically first usedTMOr Millipore PelliconTMUltrafiltration unit) to concentrate the supernatant from such an expression system. When the antibody is secreted into the culture medium, the recombinant host cells can also be isolated from the cell culture medium, for example, by tangential flow filtration.
The term "cell lysate" as used herein refers to an aqueous solution of cellular biological material comprising antibodies, wherein a majority of the cells of the cellular material have been destroyed and released their internal components.
In one embodiment, the cell lysate is prepared from whole cells.
In the case of whole cell lysates, it will be appreciated that after the cell membrane is ruptured, the cell lysate can be treated to remove organelles (e.g., nuclei) larger than about 2 microns. Thus, for example, whole cell lysates may be centrifuged to pellet the nuclei from the cell lysates. Exemplary centrifugation conditions include centrifugation at 500-.
Cell lysates can be prepared from any cell expressing the antibody. The cell may be eukaryotic (e.g., mammalian, plant, fungal) or prokaryotic (bacterial).
In one embodiment, the cell secretes the antibody into its cytoplasm.
The cells may be genetically modified to express antibodies. In another embodiment, the cell is not genetically modified.
Exemplary cells contemplated include, but are not limited to, gram-negative bacterial cells, such as e.coli; gram-positive bacterial cells, e.g. Bacillus pumilus (B.), (B.)Bacillus brevis) Bacillus subtilis preparation (B)Bacillus subtilis) Bacillus megaterium (B.megaterium) (B.megaterium)Bacillus megaterium) And lactobacilli (e.g. lactobacillus zeae/casei: (a)Lactobacillus zeae/casei) Or Lactobacillus paracasei: (Lactobacillus paracasei) ); yeast cells, such as Pichia pastoris (A.), (B.) (Pichia pastoris) Saccharomyces cerevisiae (A)Saccharomyces cerevisiae) Hansenula polymorpha (Hansenula polymorpha) (II)Hansenula polymorpha) Schizosaccharomyces pombe (Schizosaccharomyces pombe)Schizosaccharomyces pombe) Schwann yeast West (Schwann yeast)Schwanniomyces occidentalis) Kluyveromyces lactis (A), (B), (CKluyveromyces lactis) And yarrowia lipolytica: (Yarrowia lipolytica) (ii) a Filamentous fungi, e.g. Trichoderma (Trichoderma) And Aspergillus (Aspergillus) (ii) a An insect cell; mammalian cells, including Chinese Hamster Ovary (CHO) cells and plant cells.
In one embodiment, the cell has been immortalized and is part of a cell line-e.g., a hybridoma. As noted, the separation method of this aspect of the invention is carried out by contacting the antibody-containing medium with an aggregate of a non-ionic detergent, a hydrophobic chelator, and a metal ion.
Examples of cell culture media for culturing antibody-producing cells include hybridoma culture media-e.g., serum-free hybridoma culture media. Such media are readily available from companies such as Gibco, Thermo Fisher Scientific and Sigma-Aldrich.
In one embodiment, the culture medium comprises serum albumin, such as horse serum albumin (HAS) or Bovine Serum Albumin (BSA).
Preferably, the serum albumin is present at a concentration of less than 0.5mg/ml, for example between 0.1-0.5 mg/ml.
Prior to this step, the medium may optionally be clarified.
The term "clarified" as used herein refers to a sample (i.e., a cell suspension) that has been subjected to a solid-liquid separation step (including one or more of centrifugation, microfiltration, and depth filtration) to remove host cells and/or cell debris. The clarified fermentation broth may be a cell culture supernatant. Clarification is sometimes referred to as a preliminary or initial recovery step and is generally performed prior to any chromatography or similar step.
The term "nonionic detergent" refers to a detergent comprising an uncharged hydrophilic head group. Some non-ionic detergents are based on polyoxyethylene or glycosides. Common examples of the former include the Tween, Triton and Brij series. These materials are also known as ethoxylates or polyglycolates and their metabolite nonylphenol. Glycosides have a sugar as their uncharged hydrophilic head group. Examples include octyl thioglucoside and maltoside. HEGA and MEGA series detergents are similar, having a sugar alcohol as the head group.
According to a particular embodiment, the non-ionic detergent is a polysorbate surfactant. Examples of such include, but are not limited to,
In one embodiment, the non-ionic detergent is
Other exemplary nonionic detergents contemplated by the present invention include those belonging to the Pluronic family (e.g., F-68 and F-127).
The term "chelating agent" as used herein refers to a compound that binds metal ions from solution by forming or the presence of two or more separate coordination bonds between a multidentate ligand and a single central atom. The chelating agent of this aspect of the invention is capable of chelating metal ions for separation. Preferably, the chelating agent is electrostatically (non-covalently) bound to the metal ion. According to a particular embodiment, the chelating agent is capable of chelating metal ions at a chelating agent to metal ratio of 2:1 or greater.
The hydrophobicity of the chelating agent enables it to partition into aggregates of non-ionic detergents. In one embodiment, the chelating agent is capable of intercalating into aggregates of the non-ionic detergent.
In one embodiment, the hydrophobic chelating agent comprises at least 8 carbons (e.g., in a chain or in a ring) and does not comprise a charged group.
In some embodiments, the hydrophobic chelating agent is 8-hydroxyquinoline or a derivative thereof. Exemplary derivatives of 8-hydroxyquinoline include, but are not limited to, 2-methyl-8-hydroxyquinoline (CH3-HQ), 5, 7-dichloro-2-methyl-8-hydroxyquinoline (Cl2-CH3-HQ), 5, 7-dibromo-8-hydroxyquinoline (Br2-HQ), 5-sulfo-7-iodo-8-hydroxyquinoline (ferron), and 5-sulfo-8-hydroxyquinoline (SO 3H-HQ).
In some embodiments, the hydrophobic chelating agent comprises a phenanthroline, such as a 1, 10-phenanthroline. Other phenanthrolines not substituted with hydrophilic substituents are also contemplated.
Exemplary hydrophobic phenanthrolines include, but are not limited to, bathophenanthroline and N- (1, 10-phenanthrolin-5-yl) alkylamides, the alkyl group being 1-10 carbon atoms in length. Exemplary N- (1, 10-phenanthrolin-5-yl) alkylamide compounds include N- (1, 10-phenanthrolin-5-yl) formamide (Phen-C1), N- (1, 10-phenanthrolin-5-yl) acetamide (Phen-C2), N- (1, 10-phenanthrolin-5-yl) propionamide (Phen-C3), N- (1, 10-phenanthrolin-5-yl) butyramide (Phen-C4), N- (1, 10-phenanthrolin-5-yl) valeramide (Phen-C5), N- (1, 10-phenanthrolin-5-yl) hexanamide (Phen-C6), N- (1, 10-phenanthrolin-5-yl) heptanamide (Phen-C7), N- (1, 10-phenanthroline-5-yl) octanoamide (Phen-C8), N- (1, 10-phenanthroline-5-yl) nonanamide (Phen-C9), and N- (1, 10-phenanthroline-5-yl) decanoamide (Phen-C10).
In some such embodiments, the phenanthroline is selected from the group consisting of bathophenanthroline, N- (1, 10-phenanthrolin-5-yl) hexanamide (Phen-C6), N- (1, 10-phenanthrolin-5-yl) decanamide (Phen-C10), and N- (1, 10-phenanthrolin-5-yl) octanamide (Phen-C8).
Throughout, "alkylamide" describes — NH-C (= O) -R, where R is an alkyl group.
The term "alkyl" describes saturated aliphatic hydrocarbons including straight and branched chain groups. Preferably, the alkyl group is 1 to 20 carbon atoms in length. Whenever a numerical range such as "1 to 20" is specified herein, this means that the group (in this case, alkyl) can contain 1 carbon atom, 2 carbon atoms, 3 carbon atoms, and the like, up to and including 20 carbon atoms. More preferably, the alkyl group is a medium size alkyl group having 1 to 10 carbon atoms. Alkyl groups may be substituted or unsubstituted. A substituted alkyl group may have one or more substituents, wherein each substituent may independently be, for example, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, and heteroaryl. Additional substituents may include, for example, hydroxyalkyl, trihaloalkyl, heteroalicyclic, amine, halide, sulfonate, sulfoxide, phosphonate, hydroxy, alkoxy, aryloxy, thiol, thioalkoxy, thioaryloxy, cyano, nitro, azo, sulfonamide, C-carboxylate, O-carboxylate, N-thiocarbamate, O-thiocarbamate, urea, thiourea, N-carbamate, O-carbamate, C-amide, N-amide, amidino, guanidine, and hydrazine, so long as the functionality of the chelating agent is maintained.
In some embodiments, the phenanthroline is Phen-C10 or Phen-C8.
Further examples of hydrophobic chelating agents include acidic organophosphorus chelating agents such as DEHPA, EHEHPA and DTMPPA; neutral organophosphorus chelating agents (e.g., TBP and tri-N-octylphosphine oxide (TOPO)), bifunctional organophosphorus chelating agents (e.g., CMPO and N, N' -tetraoctyl-3-oxamenthane diamide (todda)); basic chelating agents, such as tri-n-octylamine (TOA) and trioctylmethylammonium chloride. Other chelating agents known to those skilled in the art may also be used, including hydroxyoximes (e.g., 5, 8-diethyl-7-hydroxy-6-dodecaneoxime and 2-hydroxy-5-nonylphenylethyloxime), crown ethers (e.g., di-tert-butyl-dicyclohexyl-18-crown-6), and dithiosemicarbazones.
According to some embodiments, the hydrophobic chelating agent is present in the aqueous solution at a concentration in the range of about 0.1% to about 10% (v/v), such as about 0.5% to about 10% (v/v), about 1% to about 10% (v/v), such as about 5%, about 6%, about 7%, about 8%, about 9% or about 10% of a 20mM chelating agent solution.
In some embodiments, the metal ion is a divalent metal ion.
In some embodiments, the divalent metal ion is selected from Zn2+、Fe2+、Mn2+、Ni2+And Co2+. Preferably, the divalent metal ion is Zn2+Or Fe2+。
In some embodiments, the metal ion is present in the aqueous solution at a concentration in the range of about 0.1% to about 10% (v/v), such as about 0.5% to about 10% (v/v), about 1% to about 10% (v/v), about 5%, about 6%, about 7%, about 8%, about 9%, or about 10% of a 50 mM metal ion solution.
The incubation conditions are such that aggregates comprising metal ions, hydrophobic chelating agent and non-ionic detergent are formed.
Thus, for example, the production of aggregates is generally conducted at a temperature of from about 0 ℃ to about 25 ℃, and more preferably from about 4 ℃ to about 25 ℃. Aggregates of this aspect of the invention are typically between 10-500 nM, 10-200 nM, 1-100 mM, or 10-100 mM.
The concentration of salt (e.g., NaCl) in the aggregate is generally less than 100 mM, and more preferably less than 50 mM. In one embodiment, the salt concentration is below 40 mM, below 30 mM, below 20mM, below 10 mM or even below 5 mM. Exemplary ranges include 20-100 mM, 20-50 mM, 0-40 mM, 0-30 mM, 0-25 mM, 0-20 mM. In a particular embodiment, the salt concentration is about 25 mM.
In some embodiments, contacting the non-ionic detergent with the hydrophobic chelating agent is performed prior to contacting with the metal ion.
In other embodiments, contacting the non-ionic detergent with the hydrophobic chelating agent is performed simultaneously with contacting with the metal ion.
In still other embodiments, the hydrophobic chelating agent is first contacted with the metal ion and then contacted with the nonionic detergent. Once the aggregates are formed, they are contacted with the cell lysate under conditions that allow partitioning of the antibody (present in the cell lysate) into the aggregates.
Once this occurs (seconds to hours-e.g. 5 minutes to 1 hour), precipitation of the complex can be promoted by centrifugation (e.g. ultracentrifugation), although in some cases (e.g. in the case of large complexes) centrifugation is not necessary or very gentle centrifugation can be used (thus making the solution denser, e.g. for 1-5 minutes at 13K).
After precipitation, the antibody may be released from the precipitated complex, i.e., solubilized.
Initially, the precipitate can be washed-for example, with a low salt solution (e.g., less than 50 mM, e.g., 20mM NaCl solution).
The extraction can be carried out with a buffer having a pH between 3 and 6, and more preferably between 3.8 and 5. In one embodiment, the buffer is a carboxylic acid buffer, examples of which include (but are not limited to) sodium acetate and sodium citrate. An exemplary pH for sodium acetate is about pH 4.6.
In another embodiment, the buffer comprises an amino acid. In one embodiment, the buffer comprises a single amino acid. In another embodiment, the buffer comprises at least two amino acids.
In one embodiment, the amino acid is one that can compete for: (i) hydrophobic interactions between antibody side chains and detergent aggregates (e.g., valine or isoleucine); (ii) ionic and/or H-bond interactions between antibody side chains and detergent aggregates (e.g., aspartic acid, glutamic acid, or arginine); or (iii) metal-chelating interactions between antibody side chains and detergent aggregates (e.g., histidine).
In a particular embodiment, the amino acid buffer is glycine, valine, or isoleucine. In another embodiment, the amino acid buffer is isoleucine.
Exemplary pH of the amino acid buffer is about pH 3.8 or
The sample may be heated for a period of time to enhance the extraction-e.g. (1-60 minutes), 1 minute, 5 minutes, 10 minutes. The temperature is chosen such that it does not affect the activity of the extracted antibody and does not cause the detergent aggregates to undergo solubilization. Exemplary temperatures are between 25-35 ℃. According to a particular embodiment, the sample is heated at 32 ℃ for 5 minutes.
To increase the purity of the released antibody, salts may be added to the buffer (e.g., between 5-50 mM NaCl or 10-20 mM NaCl). To increase the amount of antibody released from the complexed precipitate, the inventors contemplate the use of a buffer without salt. However, it will be appreciated that the purity of the released antibody may then be compromised.
Depending on the intended use of the isolated and optionally solubilized antibody, the protein (membrane or cytosol) or substance to which it binds may be subjected to further purification steps. This can be done using a variety of biochemical methods well known in the art. Examples include, but are not limited to, fractionation on hydrophobic interaction chromatography (e.g., on phenyl sepharose), ethanol precipitation, isoelectric focusing, reverse phase HPLC, silica gel chromatography, heparin sepharose chromatography, anion exchange chromatography, cation exchange chromatography, chromatofocusing, SDS-PAGE, ammonium sulfate precipitation, hydroxyapatite chromatography, gel electrophoresis, dialysis, virus inactivation (e.g., virus filtration), and ultrafiltration.
Examples of additional purification steps (and sequences in which they may be performed) are outlined in fig. 5B.
Anion exchange chromatography is a method of separation based on the charge of a substance using an ion exchange resin containing positively charged groups, such as Diethylaminoethyl (DEAE). In solution, the resin is coated with positively charged counter ions (cations). The anion exchange resin will bind to negatively charged molecules, displacing the counter ions.
Cation exchange chromatography is a method of performing separation based on the charge of a substance using an ion exchange resin containing negatively charged groups such as Carboxymethyl (CM), Sulfoethyl (SE), Sulfopropyl (SP), phosphate (P), and sulfonate (S). In solution, the resin is coated with negatively charged counter ions (anions). The cation exchange resin will bind to positively charged molecules, displacing the counter ions.
The phrase "viral inactivation" as used herein refers to a reduction ("inactivation") of the activity of a foreign envelope virus in a particular sample. This reduction in enveloped virus activity may be on the order of about 3 Log Reduction Factors (LRFs), preferably about 4 LRFs, more preferably about 5 LRFs, even more preferably about 6 LRFs.
Any one or more of a variety of viral inactivation methods may be used, including heat inactivation (pasteurization), pH inactivation, solvent/detergent treatment, UV and gamma irradiation, and the addition of certain chemical inactivators, such as β -propiolactone or phenanthroline copper, for example, as in U.S. patent No. 4534972, the entire teachings of which are incorporated herein by reference.
Methods of pH viral inactivation include, but are not limited to, incubating the mixture at low pH for a period of time, and then neutralizing the pH. In certain embodiments, the mixture is incubated at a pH of between about 2-5, preferably at a pH of between about 3-4, and more preferably at a pH of about 3.6.
The pH of the sample mixture may be lowered by any suitable acid, including, but not limited to, citric acid, acetic acid, caprylic acid, or other suitable acids. The choice of pH level depends largely on the stability characteristics of the antibody product and the buffer composition. The quality of the target antibody during low pH viral inactivation is known to be affected by pH and the duration of the low pH incubation. In certain embodiments, the low pH incubation duration will be from 0.5 hours to 2 hours, preferably from 0.5 hours to 1.5 hours, and more preferably the duration is about 1 hour. In addition to protein concentration, virus inactivation depends on these same parameters, which may limit inactivation at high concentrations.
Thus, appropriate parameters of protein concentration, pH, and duration of inactivation can be selected to achieve the desired level of viral inactivation.
In certain embodiments, virus filtration is performed. This can be achieved by using a suitable filter. A non-limiting example of a suitable filter is Ultipor DV50 from Pall CorporationTMAnd (3) a filter. In certain embodiments, alternative filters are used for virus inactivation, such as, but not limited to, Sartorius filters, Viresolve @filters (Millipore, Billerica, Mass.); zeta Plus VR filters (CUNO; Meriden, Conn.); and a Planova ™ filter (Asahi Kasei Pharma, Planova Division, Buffalo Grove, 111.).
Ultrafiltration is described in detail in: microfiltration and Ultrafiltration: Principles and applications, L. Zeman and A. Zydney (Marcel Dekker, Inc., New York, N.Y., 1996); and Ultrafiltration Handbook, Munir Cheryan (technical Publishing,1986; ISBN number 87762-. A preferred method of Filtration is tangential flow Filtration, as described in Millipore catalog entitled "Pharmaceutical Process Filtration Catalogue" page 177-202 (Bedford, Mass., 1995/96). Ultrafiltration is generally considered to mean filtration using a filter having a pore size such that proteins with an average size of 50 kDa (for example) or less can be transferred. By using a filter with such a small pore size, the volume of the sample can be reduced by allowing the sample buffer to permeate through the filter while retaining the antibody behind the filter.
Diafiltration is a process that uses an ultrafilter to remove and exchange salts, sugars and non-aqueous solvents, separate from bound species, remove low molecular weight species and/or cause rapid changes in ionic and/or pH environment. By adding solvent to the solution to be ultrafiltered at a rate approximately equal to the ultrafiltration rate, trace solutes can be removed most efficiently. This washes traces of the species from the solution at a constant volume, effectively purifying the retained antibody. In certain embodiments of the invention, a diafiltration step is employed to exchange various buffers used in conjunction with the invention, and to remove impurities from the antibody, optionally prior to further chromatography or other purification steps.
In one embodiment, the isolated antibody is crystallized.
The term "crystallization" as used herein refers to the solidification of a target molecule to form a regularly repeating internal arrangement of its atoms, and often an external plane.
Several crystallization methods known in the art may be applied to the sample to facilitate crystallization of the target molecule. Examples of crystallization methods include, but are not limited to, free interface diffusion [ Salemme, F.R. (1972) Arch. biochem. Biophys. 151: 533-.
Currently, the pendant drop method is the most commonly used method for growing macromolecular crystals from solution, and this method is particularly suitable for producing protein crystals. Typically, a droplet containing a protein solution is spotted on a cover slip and suspended in a closed chamber containing a reservoir with a higher concentration of precipitating agent. Over time, the solution in the droplet equilibrates with the reservoir by diffusing water vapor from the droplet, thereby slowly increasing the concentration of protein and precipitating agent within the droplet, which in turn causes the protein to precipitate or crystallize.
In another embodiment, the protein is subjected to 2D gel electrophoresis.
Reagents for purifying antibodies may be provided as kits.
Accordingly, in still another aspect of the present invention, there is provided a kit for purifying a protein, comprising a hydrophobic chelator, a metal ion, a non-ionic detergent and a buffer at a pH between 3 and 6.
These components have been described above.
In an alternative configuration, the kit may comprise a hydrophobic chelating agent, a polysorbate surfactant, and a metal ion.
The hydrophobic chelating agent is preferably packaged in a container separate from the metal ions.
The kit may further comprise a protease inhibitor.
Protease inhibitors include serine protease inhibitors, cysteine protease inhibitors, aspartic protease inhibitors, and metalloprotease inhibitors.
In one embodiment, the kit comprises at least two, at least three, at least four, at least five, at least six protease inhibitors.
Examples of protease inhibitors include, but are not limited to, AEBSF, bestatin, E-64, pepstatin A, phosphoramidon, leupeptin, and aprotinin.
The protease inhibitors may be packaged individually or in a single container (i.e., as a mixture).
Protease inhibitor cocktail is commercially available, for example from Sigma Aldrich.
Preferably, the container of the kit of this aspect of the invention comprises a label. Suitable containers include, for example, bottles, vials, syringes, and test tubes. The container may be formed from a variety of materials, such as glass or plastic.
In addition, other additives such as stabilizers, buffers, blockers, etc. may also be added.
It is expected that during the life of a patent maturing from this application many relevant hydrophobic chelating agents will be developed and the scope of the term hydrophobic chelating agent is intended to include all such new technologies a priori.
The term "about" as used herein means ± 10%.
The terms "comprising", "including", "having" and variations thereof mean "including but not limited to".
The term "consisting of means" including and limited to.
The term "consisting essentially of … …" means that the composition, method, or structure may include additional ingredients, steps, and/or components, but does not materially alter the basic and novel characteristics of the claimed composition, method, or structure.
As used herein, the singular forms "a", "an" and "the" include plural referents unless the context clearly dictates otherwise. For example, the term "a compound" or "at least one compound" may include a plurality of compounds, including mixtures thereof.
Throughout this application, various embodiments of the present invention may be presented in a range format. It is to be understood that the description of the range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the invention. Accordingly, the description of a range should be considered to have specifically disclosed all the possible sub-ranges as well as individual numerical values within that range. For example, description of a range (e.g., 1-6) should be considered to have specifically disclosed sub-ranges (e.g., 1-3, 1-4, 1-5, 2-4, 2-6, 3-6, etc.) as well as individual numbers within that range (e.g., 1, 2, 3, 4, 5, and 6). This applies regardless of the breadth of the range.
The term "method" as used herein refers to manners, means, techniques and procedures for accomplishing a given task including, but not limited to, those manners, means, techniques and procedures either known to, or readily developed from known manners, means, techniques and procedures by practitioners of the chemical, pharmacological, biological, biochemical and medical arts.
It is appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable subcombination or as suitable in any other described embodiment of the invention. Certain features described in the context of various embodiments should not be considered essential features of those embodiments, unless the embodiment is inoperative in the absence of those elements.
Various embodiments and aspects of the present invention as described above and as claimed in the claims section below are supported experimentally in the following examples.
Examples
Reference is now made to the following examples, which together with the above descriptions illustrate some embodiments of the invention in a non-limiting manner.
Generally, nomenclature used herein and laboratory procedures utilized in the present invention include molecular, biochemical, microbiological and recombinant DNA techniques. This technique is explained extensively in the literature. See, for example, "Molecular Cloning: Alaborory Manual" Sambrook et al, (1989), "Current Protocols in Molecular Biology" Volumes I-III Autosubel, R.M., ed. (1994); Ausubel et al, "Current Protocols in Molecular Biology", John Wiley and Sons, Baltimore, Maryland (1989); Perbal, "A Practical Guido Molecular Cloning," John Wiley and Sons&Sons, New York (1988); Watson et al, "Recombinant DNA", Scientific American Books, New York; Birren et al (eds) "Genome Analysis: A Laboratory Manual Series", Vols.1-4, Cold Spring Harbor Laboratory Press, New York (1998); e.g., U.S. Pat. Nos. 4666828, 4683202, 4801531. 5192659 and 5272057; "Cell Biology: organism Handbook", Volumes I-III Cells, J.E., ed. (1994), "Culture of animal Cells-A Manual of Basic Technique" by fresh, Wiley-Liss, N.Y. (1994), Third Edition; "Current Protocols in Immunology" Volumes I-IIIColigan J.E., ed. (1994); "Stits et al (eds)," Basic and clinical Immunology "(8)thEdition), Appleton&Lange, Norwalk, CT (1994); Mishell and Shiigi (eds), "Selected Methods in Cellular Immunology", W.H. Freeman and Co., New York (1980); useful immunoassays are extensively described in the patent and scientific literature, see, e.g., U.S. Pat. Nos. 3791932, 3839153, 3850752, 3850578, 3853987, 3867517, 3879262, 3901654, 3935074, 3984533, 3996345, 4034074, 4098876, 4879219, 5011771 and 5281521; "Oligonucleotide Synthesis" Gate, M.J., ed. (1984), "Nucleic acid hybridization" Hames, B.D., And Higgins S.J., eds. (1985), "Transmission And Transmission" Hames, B.D., And Higgins S.J., eds. (1984), "Animal cell culture" Freeze, R.I., ed. (1986), "Immobilized Cells And Enzymes" IRLPRess (1986), "A Practical Guide to Molecular Cloning" Sanbal, B., (1984) And "Methods in Enzymology" volume management 1-317, analysis "PCR," method A. primer, PCR, "primer And" primer in analysis "PCR (1996) (CSAdp. detection: PCR, reaction: primer, PCR, 1996); which is incorporated by reference in its entirety as if fully set forth herein. Other general references are provided throughout this document. The procedures therein are considered well known in the art and are provided for the convenience of the reader. All information contained therein is incorporated herein by reference.
- 上一篇：一种医用注射器针头装配设备
- 下一篇：用于治疗癌症的IL-1β结合抗体